5-Amino-1MQ (5-Amino-1-Methylquinolinium)

Comprehensive Research Analysis - NNMT Inhibitor for Metabolic Optimization

Classification: NNMT Inhibitor, Metabolic Modulator, Small Molecule Compound Chemical Formula: C₁₀H₁₁N₂⁺ Molecular Weight: 159.21 g/mol CAS Number: 42464-96-0 PubChem CID: 950107 Research Status: Preclinical (Animal Studies Only) WADA Status: Prohibited (S0 - Unapproved Substances)

1. Executive Summary

5-Amino-1-methylquinolinium (5-Amino-1MQ) is a synthetic, membrane-permeable small molecule that selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme crucial in NAD⁺ metabolism and cellular energy regulation. First characterized by researchers at the University of Texas in 2017, 5-Amino-1MQ represents a novel approach to metabolic optimization by preserving intracellular NAD⁺ levels, which may enhance fat oxidation and reduce adipose tissue accumulation [1].

Unlike traditional peptides, 5-Amino-1MQ is a positively charged quaternary ammonium compound with distinct pharmacological properties. Its mechanism centers on blocking NNMT's conversion of nicotinamide to 1-methylnicotinamide, thereby preventing NAD⁺ depletion and methyl donor consumption [2]. Animal studies demonstrate significant reductions in body weight, white adipose tissue mass, and adipocyte size with negligible toxicity [3].

Critical Limitation: As of 2025, 5-Amino-1MQ has not entered human clinical trials and remains unapproved by regulatory agencies worldwide [4]. All available dosing information is extrapolated from animal research and anecdotal reports, not evidence-based clinical protocols.

Goal Relevance:

• Achieve weight loss by enhancing fat burning and reducing fat storage
• Improve body composition by decreasing white adipose tissue mass
• Boost metabolic rate for more efficient energy use and fat oxidation
• Support longevity and vitality through increased NAD⁺ levels and cellular energy
• Enhance recovery from metabolic stress by preserving NAD⁺ and methyl donor pools
• Optimize energy levels and reduce fatigue by supporting mitochondrial function

2. Chemical Structure & Composition

Molecular Profile

Chemical Formula: C₁₀H₁₁N₂⁺ IUPAC Name: 5-Amino-1-methylquinolin-1-ium Molecular Weight: 159.21 g/mol CAS Registry Number: 42464-96-0 PubChem CID: 950107

Chemical Properties

• Charge: Positively charged quaternary ammonium compound
• Solubility: High aqueous solubility (>100 mg/mL) in water, pH-buffered solutions, and simulated gastric fluids [6]
• pKa: Estimated basic pKa of 1.45
• Membrane Permeability: High membrane permeability despite positive charge, enabling cellular uptake
• Stability: Stable in aqueous solutions; specific long-term stability data limited

Structural Classification

5-Amino-1MQ is not a peptide but rather a synthetic small molecule derived from quinolinium chemistry. Its compact structure enables:

• Oral bioavailability (unlike most peptides)
• Cellular and nuclear membrane penetration
• High selectivity for NNMT enzyme target
• Resistance to proteolytic degradation

Chemical Synthesis

First synthesized and characterized in 2017 during research into NNMT inhibitors [1]. The compound demonstrates high selectivity for NNMT without inhibiting related SAM-dependent methyltransferases or enzymes in the NAD⁺ salvage pathway, making it a precision metabolic modulator.

3. Mechanism of Action

Primary Pathway: NNMT Inhibition

5-Amino-1MQ functions as a selective, competitive inhibitor of nicotinamide N-methyltransferase (NNMT) [7]. Understanding this mechanism requires examining NNMT's normal function and the consequences of its inhibition.

NNMT Normal Function

Under typical conditions, NNMT catalyzes the following reaction:

Nicotinamide (NAM) + S-Adenosylmethionine (SAM) → 1-Methylnicotinamide (MNA) + S-Adenosylhomocysteine (SAH)

This reaction:

1. Consumes NAD⁺ precursors: Nicotinamide is a direct NAD⁺ precursor in the salvage pathway
2. Depletes methyl donors: SAM is the universal methyl donor for >200 methylation reactions
3. Produces MNA: A metabolically inactive methylated product that is excreted
4. Increases with obesity: NNMT expression is upregulated in adipose tissue of obese individuals [7]

Mechanism of 5-Amino-1MQ Inhibition

By blocking NNMT activity, 5-Amino-1MQ produces several interconnected metabolic effects:

1. NAD⁺ Preservation

• Prevents nicotinamide methylation and excretion as MNA
• Allows nicotinamide to enter NAD⁺ salvage pathway
• Increases intracellular NAD⁺ availability [8]
• NAD⁺ is critical for:
  • Mitochondrial energy production (electron transport chain)
  • Sirtuin activation (longevity proteins)
  • DNA repair mechanisms
  • Cellular stress resistance

2. Methyl Donor Conservation

• Prevents SAM consumption by NNMT
• Preserves SAM pools for other critical methylation reactions
• Supports epigenetic regulation and gene expression

3. Lipogenesis Suppression

In vitro studies show 5-Amino-1MQ:

• Significantly reduces intracellular MNA levels
• Increases intracellular NAD⁺ concentrations
• Suppresses lipogenesis in adipocytes (fat cell formation) [1]

4. Metabolic Shift Toward Fat Oxidation

By maintaining higher NAD⁺ levels, cellular metabolism shifts from fat storage to fat oxidation:

• Enhanced β-oxidation of fatty acids
• Increased mitochondrial efficiency
• Greater energy expenditure [2]

Animal Model Results

In vivo studies using diet-induced obese (DIO) mice treated with 5-Amino-1MQ demonstrated:

Body Composition Changes:

• Significantly reduced body weight
• Decreased white adipose tissue (WAT) mass
• Smaller adipocyte cell size
• Reduced cholesterol levels
• Negligible toxicity or adverse effects [1]

Metabolic Improvements:

• No impact on food intake (effect is metabolic, not appetite-based)
• Enhanced fat utilization
• Improved energy homeostasis

High Selectivity

A critical advantage of 5-Amino-1MQ is its high specificity for NNMT. It does not inhibit:

• Other SAM-dependent methyltransferases
• NAD⁺ salvage pathway enzymes
• Related metabolic enzymes

This selectivity minimizes off-target effects and potential toxicity [1].

Goal Archetype Integration

Primary Goal Alignment

When This Compound Makes Sense

• Metabolic dysfunction with stubborn fat: Individuals with visceral adiposity and metabolic syndrome markers where NNMT is likely overexpressed
• NAD+ preservation strategy: As part of a comprehensive NAD+ optimization protocol alongside precursors (NMN/NR)
• Adjunct to GLP-1 therapy: May provide complementary mechanisms (metabolic vs. appetite suppression) for weight management
• Age-related metabolic decline: Adults 40+ experiencing declining NAD+ levels and increased NNMT expression
• Research into metabolic pathways: Understanding NNMT's role in obesity and Type 2 diabetes pathophysiology

When to Choose Something Else

• Primary goal is appetite suppression: GLP-1 agonists (semaglutide, tirzepatide) are far more effective and evidence-based [20]
• Need FDA-approved therapy: 5-Amino-1MQ has no human clinical trials; GLP-1s are FDA-approved with extensive safety data
• Muscle building priority: Growth hormone secretagogues (Ipamorelin, CJC-1295) or anabolic peptides more appropriate
• Acute healing needs: BPC-157 or TB-500 are better choices for tissue repair
• Competitive athletes: WADA-prohibited (S0 category) - choose compliant alternatives
• Pregnancy/lactation: Contraindicated - unknown fetal/infant effects

4. Pharmacokinetics

Absorption

Oral Route:

• 5-Amino-1MQ displays substantial plasma exposure after oral administration in rat studies [6]
• Mean maximum plasma concentration (Cmax): 2252 ng/mL after oral dosing in rats
• High aqueous solubility (>100 mg/mL) supports oral absorption
• First-pass metabolism significantly reduces oral bioavailability compared to injectable routes

Injectable Route:

• Subcutaneous injection bypasses first-pass metabolism
• Provides more consistent bioavailability
• Recommended for research applications requiring precise dosing

Distribution

• As a small, membrane-permeable molecule, 5-Amino-1MQ readily crosses cellular membranes
• Distributes to adipose tissue (site of NNMT expression in obesity)
• Capable of nuclear membrane penetration [2]

Metabolism

• Metabolic pathways in humans remain undefined (no human studies)
• Rat studies show hepatic metabolism
• Positively charged quaternary structure may limit hepatic extraction compared to neutral compounds

Elimination

Half-Life (Rat Studies):

• Intravenous administration: 3.80 ± 1.10 hours [6]
• Oral administration: 6.90 ± 1.20 hours [6]

Implications:

• Moderate half-life suggests once or twice-daily dosing may be sufficient
• Steady-state concentrations likely achieved within 24-48 hours of consistent dosing

Excretion:

• Primary route: Likely renal (quaternary ammonium compounds typically renally cleared)
• Data on metabolite profiles limited

Critical Limitation

All pharmacokinetic data derives from rat studies. Direct extrapolation to humans is unreliable due to:

• Species differences in metabolism
• Differences in NNMT tissue expression
• Potential variations in bioavailability and clearance [6]

Human pharmacokinetic studies are urgently needed to establish clinical dosing protocols.

5. Dosing Protocols

5-Amino-1MQ has NOT been tested in human clinical trials. All dosing information below is derived from:

1. Animal research (primarily mice and rats)
2. Anecdotal reports from research chemical users
3. Extrapolations from NNMT biology

None of the following constitutes evidence-based clinical guidance. These protocols are presented solely for research reference purposes.

Base Dosing Guidelines (Anecdotal, Not Evidence-Based)

Standard Range

• Typical dose: 50–100 mg per day orally [9]
• Frequency: Once daily (due to ~7-hour half-life) or divided into twice-daily doses (25–50 mg BID) for more stable blood levels [10]
• Duration: Protocols vary from 4–12 weeks, with many users cycling on/off

Administration Routes

• Oral (capsules/tablets): Most common, convenient, but subject to first-pass metabolism
• Subcutaneous injection: Reconstituted from powder, provides superior bioavailability [2]

Body Weight-Based Adjustments

Since 5-Amino-1MQ targets metabolic pathways influenced by body composition, anecdotal protocols adjust dosing by weight:

Animal Research Reference:

• Mice received 20 mg/kg/injection subcutaneously, 3× daily = ~34 mg/kg/day total [10]
• Rat studies suggest tolerable oral dose of ~100 mg/kg in rodents [9]
• Human equivalent doses cannot be reliably calculated from rodent data

Sex-Specific Considerations

No published research differentiates dosing by sex. Theoretical considerations:

Males

• Higher baseline NNMT expression in visceral adipose tissue (common in android obesity)
• May respond to standard dosing (75–100 mg/day)

Females

• Hormonal fluctuations (estrogen) may influence NNMT expression
• Subcutaneous fat distribution (gynoid obesity) may have different NNMT activity
• No data supports reduced dosing; standard protocols appear similar

Contraindication: Not recommended during pregnancy or breastfeeding due to unknown effects on fetal/infant NAD⁺ metabolism [11].

Age-Stratified Dosing

NNMT expression and NAD⁺ metabolism change significantly with age, affecting optimal dosing strategies. NNMT is overexpressed in skeletal muscles with aging and linked to impairment of the NAD+ salvage pathway and increased muscle stem cell senescence [19].

Oral-Specific Dosing Considerations

Since 5-Amino-1MQ is primarily administered orally (unlike injectable peptides):

Absorption Variables:

• First-pass metabolism: Hepatic processing reduces bioavailability compared to subcutaneous injection
• Food timing: Taking with food may reduce GI discomfort but slightly slow absorption
• Gastric pH: Age-related changes in stomach acid may affect dissolution (older adults often have higher gastric pH)

Practical Adjustments:

• Once daily dosing: Preferred for compliance given ~7-hour half-life
• Morning administration: Aligns with circadian NAD+ patterns; avoids potential sleep disruption
• Divided dosing (BID): 25-50 mg AM + 25-50 mg early PM for more stable levels in those experiencing peaks/troughs

Age-Specific Oral Considerations:

No clinical trials in any age group exist to validate these assumptions. All dosing is extrapolated from animal pharmacokinetics and anecdotal reports.

Activity Level Adjustments

Metabolic activity influences NAD⁺ demand and NNMT expression:

Note: Some anecdotal reports suggest difficulty with cardiovascular exercise while using 5-Amino-1MQ [12], possibly due to altered energy metabolism during adaptation.

Goal-Specific Dosing

Fat Loss / Metabolic Optimization

• Dose: 75–100 mg/day oral
• Cycle: 8–12 weeks on, 4 weeks off
• Adjuncts: Often combined with NAD⁺ precursors (NMN, NR) to maximize NAD⁺ availability [2]

Anti-Aging / NAD⁺ Preservation

• Dose: 50–75 mg/day oral
• Cycle: Longer protocols (12+ weeks) with periodic cycling
• Stack: Combine with resveratrol, quercetin, or other sirtuin activators

Research Applications

• Dose: Variable based on study design
• Route: Injectable preferred for bioavailability consistency
• Monitoring: Regular blood work (liver function, lipid panel, glucose)

Cycling Protocols

Most anecdotal protocols recommend cycling to prevent tolerance or long-term metabolic adaptation:

Common Cycles:

• 8 weeks on / 4 weeks off
• 12 weeks on / 4 weeks off
• Continuous use: Not recommended without medical supervision

Rationale for Cycling:

• Unknown long-term effects on NNMT expression
• Theoretical concern about metabolic downregulation
• Allows assessment of sustained benefits post-cessation

Reconstitution (Injectable Use)

For subcutaneous administration:

1. Powder Storage: Store lyophilized powder at -20°C until reconstitution
2. Reconstitution Fluid: Use bacteriostatic water (0.9% benzyl alcohol)
3. Concentration Example:
   • 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL solution
   • For 50 mg dose: Inject 10 mL (impractical; oral preferred for this dose)
4. Reconstituted Storage: Refrigerate at 2–8°C, use within 28 days

Note: Given high oral bioavailability, injectable use is less common for 5-Amino-1MQ compared to peptides like BPC-157 or TB-500.

6. Clinical Research & Evidence

Human Studies

As of 2025: ZERO human clinical trials published or registered for 5-Amino-1MQ [4].

• No Phase I safety trials
• No Phase II efficacy trials
• No Phase III comparative trials
• No post-market surveillance data

Critical Gap: All claims about human efficacy, safety, and dosing are entirely speculative and based on rodent data.

Animal Research

Primary Study: Kraus et al. (2014) - Cell Metabolism

Citation: Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014.

Study Design:

• Diet-induced obese (DIO) mice
• Treatment: 5-Amino-1MQ subcutaneous injection
• Dose: 20 mg/kg per injection, 3× daily (total ~34 mg/kg/day)
• Duration: Not specified in abstracts reviewed

Key Findings:

1. Body Weight: Significant reduction compared to controls
2. White Adipose Tissue: Marked decrease in WAT mass
3. Adipocyte Size: Smaller fat cells observed histologically
4. Cholesterol: Reduced serum cholesterol levels
5. Food Intake: No change (effect is metabolic, not appetite-suppressing)
6. Toxicity: Negligible adverse effects observed

In Vitro Findings:

• Reduced intracellular 1-methylnicotinamide (MNA)
• Increased intracellular NAD⁺ levels
• Suppressed lipogenesis in cultured adipocytes

Research Quality: High-quality preclinical study published in a top-tier journal, but animal data cannot substitute for human trials.

Supporting Studies

NAD+ Metabolism Research:

• Hong S, et al. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med. 2015.
• Demonstrated NNMT's role in obesity and Type 2 diabetes pathophysiology
• Showed NNMT expression correlates with adiposity in humans

Pharmacokinetic Study:

• Neelakantan H, et al. Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma. J Chromatogr B. 2021.
• Established rat pharmacokinetics (half-life, bioavailability)
• Critical for dosing extrapolation, but species differences limit human relevance

Research Quality Assessment

Conclusion: Evidence base is preclinical only. Human translation is speculative.

Knowledge Gaps

1. Human Safety: No toxicology data, long-term safety unknown
2. Human Efficacy: No proof that rodent metabolic effects occur in humans
3. Dosing: No PK/PD studies to establish optimal human dose
4. Drug Interactions: Unknown interactions with medications, supplements
5. Special Populations: No data on safety in elderly, pregnant, or diseased populations
6. Mechanism Validation: NNMT inhibition in humans not directly measured in published studies

7. Safety Profile

Common Side Effects (Anecdotal Reports)

Reported Frequency: Uncommon [12]

Anecdotal user reports (not clinical data) describe:

Onset: Most side effects occur during initial 1–2 weeks as metabolism adapts to increased NAD⁺ availability [12].

Serious Adverse Events

Documented Cases: None in published literature.

However, absence of evidence ≠ evidence of absence. No systematic adverse event monitoring exists.

Theoretical Concerns:

1. Cardiovascular Effects: Potential sympathomimetic effects due to altered energy metabolism
2. Hepatotoxicity: Unknown long-term effects on liver function
3. Allergic Reactions: Rare, but reported in anecdotal use [13]

Contraindications

Absolute Contraindications [11]

1. Pregnancy: Unknown effects on fetal NAD⁺ metabolism; avoid entirely
2. Breastfeeding: Unknown excretion in breast milk; avoid
3. Severe Kidney Disease: Quaternary ammonium clearance may be impaired
4. Severe Liver Disease: Hepatic metabolism required; cirrhosis increases risk

Relative Contraindications [11]

Use with extreme caution (medical supervision required):

• Uncontrolled Hypertension: Potential sympathomimetic effects
• Hyperthyroidism: May exacerbate hypermetabolic state
• Active Cardiac Disease: Altered energy metabolism may stress compromised hearts
• Diabetes (on medication): May alter glucose metabolism; monitor closely

Drug Interactions - Comprehensive

CRITICAL LIMITATION: No formal drug interaction studies exist for 5-Amino-1MQ. All interactions below are theoretical, based on mechanism of action, pathway overlap, and extrapolation from NNMT biology. Consult a healthcare provider before combining with any medication.

Prescription Medications

Other Compounds (Stacking)

NAD+ Pathway-Specific Interactions

Since 5-Amino-1MQ's primary mechanism involves the NAD+ salvage pathway, understanding interactions with this pathway is critical:

Supplements

Foods/Timing

Long-Term Safety

Unknown. No human data beyond anecdotal short-term use (weeks to months).

Animal Data: Mice treated with 60 mg/kg/day (far exceeding typical anecdotal human doses) showed negligible toxicity [1]. However:

• Rodent lifespan studies needed
• Chronic NNMT inhibition effects on epigenetics, gene expression unknown
• Potential for metabolic adaptation or tolerance

Special Populations

Pediatric

• Not recommended: Developing metabolism, unknown effects on growth
• No safety data

Geriatric

• Use with caution: Comorbidities common, polypharmacy risks
• May have higher NNMT expression, potentially benefiting from NAD⁺ restoration
• Requires medical supervision

Pregnancy / Lactation

• Contraindicated: No safety data, theoretical fetal/infant risk [11]

Summary: Safety Assessment

Animal Safety: Appears well-tolerated at doses producing metabolic effects in rodents [1].

Human Safety: Entirely unknown due to absence of clinical trials. Anecdotal reports suggest mild, transient side effects, but:

• No systematic monitoring
• Self-selection bias (healthy users more likely to report)
• Long-term consequences unknown
• Serious adverse events may be underreported

Recommendation: 5-Amino-1MQ should only be used in research contexts with appropriate medical oversight and informed consent. It is not suitable for general consumer use given the lack of safety data.

8. Administration & Practical Application

Routes of Administration

Oral (Capsules / Tablets)

Most Common Route

Advantages:

• Convenient, non-invasive
• No injection training required
• High aqueous solubility supports absorption [6]

Disadvantages:

• Subject to first-pass hepatic metabolism
• Bioavailability lower than injectable route [2]
• Inter-individual variability in absorption

Typical Products:

• 15 mg capsules (Paramount Peptides, others)
• 50 mg capsules (various research suppliers)
• Take 3–6 capsules daily to achieve 50–100 mg total dose

Subcutaneous Injection

Preferred for Research Applications

Advantages:

• Bypasses first-pass metabolism
• More consistent bioavailability
• Lower total dose required

Disadvantages:

• Requires reconstitution skills
• Injection technique needed
• Less convenient than oral

Reconstitution Protocol:

1. Lyophilized powder (10 mg, 50 mg vials available from research suppliers)
2. Add bacteriostatic water (volume depends on desired concentration)
3. Mix gently (do not shake vigorously)
4. Store reconstituted solution at 2–8°C
5. Use within 28 days

Injection Technique:

• Use 27-30 gauge insulin syringe
• Inject into subcutaneous tissue (abdomen, thighs, upper arms)
• Rotate injection sites to prevent lipohypertrophy
• Typical volume: 0.5–1.0 mL per injection

Timing Considerations

Circadian Rhythm Optimization

NAD⁺ metabolism follows circadian patterns:

Morning Dosing:

• Aligns with natural metabolic peak
• Supports daytime energy production
• Reduces risk of sleep disturbances

Evening Dosing:

• Avoid late-day dosing if sleep issues occur [13]
• May interfere with sleep architecture due to metabolic activation

Twice-Daily Dosing:

• Morning + early afternoon (e.g., 8 AM and 2 PM)
• Maintains stable blood levels given ~7-hour half-life
• Reduces peak/trough fluctuations

Meal Timing

With Food:

• May reduce GI discomfort [12]
• Slows absorption slightly but improves tolerability

Fasted State:

• Potentially faster absorption
• May enhance fat oxidation effects
• Risk of nausea in sensitive individuals

Exercise Timing

Pre-Workout:

• Theoretical enhancement of fat oxidation during cardio
• Anecdotal reports of reduced exercise performance initially [12]
• Allow 2–4 weeks adaptation before intense training

Post-Workout:

• May support recovery via enhanced NAD⁺-dependent repair processes
• No specific research on timing

Combination Therapies

5-Amino-1MQ is frequently combined with complementary compounds:

NAD⁺ Precursor Stacks [2]

Rationale: 5-Amino-1MQ prevents NAD⁺ depletion; adding precursors increases NAD⁺ synthesis

Common Stack:

• 5-Amino-1MQ: 75 mg/day
• NMN (Nicotinamide Mononucleotide): 500–1000 mg/day
• OR NR (Nicotinamide Riboside): 300–600 mg/day

Benefits:

• Synergistic NAD⁺ elevation
• Maximizes mitochondrial function
• Enhanced anti-aging effects

Fat Loss Stacks

Example Protocol:

• 5-Amino-1MQ: 75 mg/day
• AOD-9604: 300 mcg/day (subcutaneous) [14]
• L-Carnitine: 2–3 g/day (supports fat oxidation)

Mechanism:

• 5-Amino-1MQ: NAD⁺ preservation, metabolic shift
• AOD-9604: Direct lipolysis stimulation
• L-Carnitine: Fatty acid transport into mitochondria

Longevity Stacks

• 5-Amino-1MQ: 50 mg/day
• Resveratrol: 500 mg/day (sirtuin activator)
• Quercetin: 500 mg/day (senolytic)
• Fisetin: 100 mg/day (senolytic)

Bloodwork Impact & Monitoring

Expected Marker Changes

Based on animal research and theoretical extrapolation from NNMT inhibition mechanisms:

NAD+ Testing - Consumer Availability

Intracellular NAD+ testing has become available through specialized consumer laboratories:

Optimal NAD+ Level Ranges (per Jinfiniti):

• Severely deficient: 0-20 uM
• Deficient: 20-30 uM
• Suboptimal: 30-40 uM
• Optimal: 40-100 uM
• Note: Levels above 100 uM may not provide additional benefits

Interpretation for 5-Amino-1MQ Users:

• Baseline intracellular NAD+ provides context for expected benefit
• Those with lower baseline NAD+ (deficient/suboptimal) may see more pronounced effects
• Follow-up testing at 4-8 weeks can confirm target engagement

Monitoring Schedule

Red Flags in Labs

Labs + Symptoms Integration

Marker-Based Dose Adjustment

Adjustment by Baseline Markers

Adjustment by Response Markers

9. Storage & Stability

Lyophilized (Powder) Storage

Optimal Conditions:

• Temperature: -20°C to -80°C (freezer storage)
• Light Protection: Store in original amber vial or foil-wrapped container
• Moisture: Desiccant packets recommended to prevent moisture absorption
• Shelf Life: Likely stable for 12–24 months when frozen; manufacturer data varies

Short-Term Storage:

• Refrigeration at 2–8°C acceptable for up to 3 months
• Room temperature (15–25°C) for brief periods (days) acceptable if necessary

Reconstituted Solution Storage

Critical Requirements:

• Temperature: 2–8°C (refrigerator) – DO NOT FREEZE reconstituted solution
• Container: Sterile glass vial with rubber stopper
• Duration: Use within 28 days of reconstitution when using bacteriostatic water
• Without Preservative: If reconstituted with sterile water (no bacteriostatic agent), use within 72 hours

Signs of Degradation:

• Discoloration (should remain clear/colorless)
• Precipitation or particulates
• Cloudiness

Capsule / Tablet Storage

• Temperature: Room temperature (15–25°C)
• Humidity: Store in dry environment; desiccant packs recommended
• Light: Protect from direct sunlight
• Shelf Life: Manufacturer-dependent; typically 1–2 years from production date

Handling Precautions

1. Contamination Prevention:

   • Use sterile technique when reconstituting
   • Alcohol-wipe vial stoppers before needle insertion
   • Never reuse needles or syringes

2. Freeze-Thaw Cycles:

   • Minimize freeze-thaw cycles of powder
   • Aliquot reconstituted solution into smaller vials if frequent use planned

3. Disposal:

   • Dispose of needles in sharps container
   • Discard expired or degraded solutions per local regulations

11. Product Cross-Reference

Core Peptides Equivalent

Status: NOT AVAILABLE

As of 2025, Core Peptides does not carry 5-Amino-1MQ in their product catalog. This was verified via:

• Website search (no product listing found)
• Product category review (not listed among 102+ peptides offered)

Implication: Cannot cross-validate Epiq Aminos 5-Amino-1MQ product against Core Peptides equivalent.

Alternative Suppliers

5-Amino-1MQ is available from various research chemical suppliers:

Common Suppliers:

1. Peptide Sciences – 60 capsules, 99% purity claimed [15]
2. Paramount Peptides – 15 mg × 60 tablets [16]
3. Swolverine – Research-grade powder and capsules [2]

Quality Considerations:

• Purity Verification: Look for third-party COA (Certificate of Analysis)
• HPLC Testing: High-performance liquid chromatography confirms identity and purity
• Mass Spectrometry: LC-MS/MS validates molecular structure
• Sterility (Injectable): Endotoxin testing for reconstitutable powders

Chemical Equivalence Validation

Since Core Peptides does not carry this product, validation relies on:

1. CAS Number Match: 42464-96-0 across all suppliers
2. Molecular Formula: C₁₀H₁₁N₂⁺
3. Molecular Weight: 159.21 g/mol
4. Appearance: White to off-white powder (lyophilized)

Red Flags (Potential Counterfeits):

• Significant price discrepancies (too cheap may indicate low purity)
• No COA provided
• Unrealistic purity claims (>99.5% difficult to achieve)
• Poor solubility (genuine 5-Amino-1MQ is highly water-soluble)

Price Comparison

Typical Market Pricing (2025):

Note: Prices fluctuate; verify current pricing directly from suppliers.

Clinical Insights from Practitioners

Source: YouTube interviews with practicing clinicians and peptide specialists

• take is quite low on average my blood glucose came down with 5 to seven points after incorporating 150 mg
• take post-workout was about 60 m gr per deciliter or my blood glucose levels that was after a leg day which is later today so I'll recheck that again but it probably Falls somewhere around 58 to 60 milligram

Expert Commentary

Dr. Dwayne Jackson — Can 5-Amino-1MQ Really Melt Fat and Slow Aging? Peptide Scientist Breaks It Down

On forums, people running research on themselves report taking 25 to 100 milligrams per day orally, usually split into two or three doses taken throughout the day, especially at the higher end of the dosing. Now remember folks, these protocols are anecdotal. They're untested and they come with unknown safety risks. So where does that really leave us? Well, pharmacologically 5 amino 1MQ blocks NMT

Clinical Insights - Practitioner Dosing

Source: YouTube practitioner interviews

• "My blood glucose came down 5 to 7 points after incorporating 150 mg of 5-Amino-1MQ. My body fat levels are progressing nicely while maintaining my caloric intake."

12. References & Citations

Primary Research Articles

1. Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014.

2. Swolverine. How 5-Amino-1MQ Works: Mechanism, Benefits, Stacking, and Cycling Guide. 2024.

3. Kraus D, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. PMC. 2018.

4. Swolverine. 5-Amino-1MQ For Beginners: Dosage, Benefits, and Peptide Stacks Explained. 2024.

5. PeptideWiki. The Legality of 5-Amino-1MQ Peptides: An Examination of Regulatory Status. 2024.

6. Neelakantan H, et al. Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma. J Chromatogr B. 2021.

7. Hong S, et al. Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes. PMC. 2021.

8. Nutritional Supplement Shop. 5-Amino-1MQ: NNMT Inhibitor for Weight Loss & Metabolism. 2024.

9. Alpha Rejuvenation. 5-Amino-1MQ Dosage: Clinical Protocol, Benefits & Administration. 2024.

10. Peptide Dosages. 5-Amino-1MQ (10 mg Vial) Dosage Protocol. 2024.

11. MediSearch. 5-Amino-1MQ Peptide: Dosage, Side Effects, and Cancer Treatment. 2024.

12. Genemedics. 5-Amino-1MQ: Benefits, Side Effects & Weight Loss. 2024.

13. The Peptide Report. 5-Amino 1MQ Side Effects: Understanding the Risks. 2024.

14. Swolverine. 5-Amino-1MQ vs AOD-9604: Fat Loss, Benefits, Stacking & Safety Guide. 2024.

15. Peptide Sciences. Buy 5-Amino-1MQ (60 Capsules) | 99% Purity (USA Made). 2024.

16. Paramount Peptides. 5-Amino-1mq (15mg) x 60 Tablets. 2024.

Regulatory Documents

• WADA Prohibited List 2026. World Anti-Doping Agency. September 2025.

Chemical Databases

• PubChem CID: 950107 - https://pubchem.ncbi.nlm.nih.gov/compound/950107
• CAS Number: 42464-96-0

Conclusion

5-Amino-1MQ represents a novel approach to metabolic optimization through selective NNMT inhibition, preserving NAD⁺ levels and potentially shifting metabolism toward fat oxidation. Animal research demonstrates promising effects on body composition with minimal toxicity. However, the complete absence of human clinical trials renders all safety and efficacy claims speculative.

For Research Purposes Only: This compound is not approved for human use and should only be utilized in controlled research settings with appropriate medical oversight and informed consent. Athletes must avoid this substance due to WADA prohibition.

Future human trials are essential to validate the compelling preclinical findings and establish evidence-based dosing protocols.

Document Version: 1.0 Last Updated: December 23, 2025 Status: Research Compound - Not FDA Approved For Research and Educational Purposes Only